All In Biotech

BLA 125294 · Sicor Biotech

Granix

Tbo-Filgrastim · Injection · Leukocyte Growth Factor

Novel

Last checked: Nov 20, 2026Latest source record: Nov 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Aug 29, 2012

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

1,183

191 Phase 3, 62 recruiting

FAERS reports

871

542 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 30, 2023.

GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 )

Mechanism: Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Tbo-Filgrastim" as an intervention, any sponsor and status, largest first.

All 1,183 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201423
201546
201658
201762
2018113
2019115
2020120
2021130
202261
202354
202437
202525
202627

Recalls

1 FDA enforcement reports for this application.

  • Jan 10, 2025 · Class II · Ongoing

    Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Granix (Tbo-Filgrastim)

2024 spending

$4.5M

Beneficiaries

2,050

5,220 claims

Per beneficiary

$2,172

$239.47 per unit

View as table
YearSpending
2020$4,189,446
2021$2,788,563
2022$2,634,694
2023$2,335,129
2024$4,452,419

Part B: Granix (Tbo-Filgrastim) · HCPCS J1447

2024 spending

$2.9M

Beneficiaries

2,992

13,183 claims

Per beneficiary

$964

2024 ASP limit $0.41 per unit

View as table
YearSpending
2020$6,486,718
2021$4,997,448
2022$4,369,262
2023$3,378,907
2024$2,885,527

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: Sicor Biotech

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.